OBJECTIVE: To determine whether thrombi or @entity432 represent a late complication persisting several years after removal of central venous lines (CVLs) in @entity1 and adolescents treated for @entity5 . METHODS: @entity1 whose treatment for malignancy included placement of a CVL that had been removed at least 2 months previously were studied during scheduled follow-up that included contrast-enhanced computed tomography. Spiral volume acquisition was used to obtain 3-mm images from the chest apices through the right hilum, and three-dimensional reconstruction of angiograms was performed. @entity715 /occlusion was defined as narrowing, obstruction, or filling @entity1150 , with or without the formation of collateral veins. Charts were reviewed to document @entity1 characteristics, previous CVL complications, administration of hyperalimentation, use of urokinase, and family history of @entity49 . RESULTS: Twenty-three @entity1 treated for solid @entity5 and 2 treated for @entity8625 or @entity706 were studied. Lines had been in place from 0.2 to 36 months (median, 7.4) and were removed at 2.3 to 121.8 months (median, 32.5) before study. Nine @entity1 received hyperalimentation for periods ranging from 2 to 38 weeks (median, 12). Four @entity1 had required urokinase instillations, and one developed @entity4264 ; 4 had a CVL-related @entity281 (two superficial and two Candida line infections). @entity432 was seen on computed tomography angiograms in 3 of the 25 @entity1 (12%; 95% confidence interval: 4.5-31%). One of the @entity1 with occlusion had @entity4264 ; none had a family history of @entity715 , use of a double lumen CVL, or multiple instillations of urokinase. CONCLUSIONS: Persistent asymptomatic @entity432 does occur as a late complication of CVL placement for treatment of childhood @entity5 , although the frequency appears low among @entity1 treated primarily for solid @entity5 . Prospective studies of large numbers of @entity1 with a broader spectrum of diagnoses are necessary to define the incidence of and risk factors for this complication and to assess the need for prevention with anticoagulation or other therapy. Pediatricians caring for @entity1 with a history of @entity5 and CVLs should be aware that these @entity1 may have persistent @entity432 that could predispose them to recurrent @entity715 or @entity5226 .

Late @entity432 of central lines in XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children', 'patient'] @entity4264 :: ('MESH:D013479', 'Disease') :: ['superior vena cava syndrome'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['childhood cancer', 'cancer', 'malignancies', 'tumors'] @entity49 :: ('MESH:D019851', 'Disease') :: ['venous thrombosis'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['defect of the deep venous system'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity5226 :: ('MESH:D011186', 'Disease') :: ['postphlebitic syndrome'] @entity8625 :: ('MESH:D015456', 'Disease') :: ['B-cell acute lymphocytic leukemia'] @entity432 :: ('MESH:D001157', 'Disease') :: ['Occlusion', 'vascular occlusion'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'Thrombosis']
@entity5 :: (MESH:D009369,Disease) :: ['pediatric malignancies']
